Who is sponsoring NCT05533983?

NCT05533983 is sponsored by Asan Medical Center.

What drugs are being tested in NCT05533983?

Interventions in NCT05533983: fecal microbiota transplantation with Nivolumab.

What condition does NCT05533983 study?

NCT05533983 studies Solid Carcinoma.

Is NCT05533983 still recruiting?

NCT05533983 is currently recruiting now. Last updated 3 December 2025.

Last reviewed 2025-12-03 · How we verify

NCT05533983: NIVO-FMT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy

Recruiting now NA Last updated 3 December 2025

What this trial tests

NA trial testing fecal microbiota transplantation with Nivolumab in Solid Carcinoma in 50 participants. Currently enrolling.

Timeline

8 March 2023

Primary endpoint
19 August 2026

19 August 2026

Quick facts

Lead sponsor	Asan Medical Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	8 March 2023
Primary completion	19 August 2026
Estimated completion	19 August 2026
Sites	1 location across South Korea

Drugs / interventions tested

fecal microbiota transplantation with Nivolumab

Conditions studied

Solid Carcinoma — all drugs for Solid Carcinoma →

Sponsor

Asan Medical Center

Who can join

19 and older, any sex, with Solid Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Immunology and immunotherapy of cholangiocarcinoma.
Greten TF, Schwabe R, Bardeesy N, Ma L, et al · · 2023 · cited 138× · PMID 36697706 · DOI 10.1038/s41575-022-00741-4
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.
Lin A, Jiang A, Huang L, Li Y, et al · · 2025 · cited 45× · PMID 39826104 · DOI 10.1080/19490976.2025.2452277
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy.
Yang Y, An Y, Dong Y, Chu Q, et al · · 2024 · cited 43× · PMID 38241975 · DOI 10.1016/j.ebiom.2024.104967
Microbiota-centered interventions to boost immune checkpoint blockade therapies.
Almonte AA, Thomas S, Zitvogel L. · · 2025 · cited 12× · PMID 40261296 · DOI 10.1084/jem.20250378
Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors.
Pum K, Lou E, Goffredo P, Jahansouz C, et al · · 2026 · PMID 41967083 · DOI 10.1093/oncolo/oyag131
Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection.
Elsheikh M, Ibrahim MA, Fares S, Bhongade M, et al · · 2026 · PMID 41891399 · DOI 10.1002/cam4.71738
Gut microbiota drives cancer evolution and therapy resistance.
Min S, Zhang Y, Zhang H, Liu Q. · · 2026 · PMID 41527087 · DOI 10.1186/s12943-025-02564-8

Verify or expand the search:

Other recruiting trials for Solid Carcinoma

Currently open trials in the same condition.

NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
NCT06894745 — PET [89Zr]DFO-starPEG in Solid Tumors · Phase 1 · recruiting
NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06475937 — A Study of DM001 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05533983 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05533983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing